(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The most effective method to Refresh the Infotainment Framework in the Volvo XC40 - 2The Universe of Impeccable Pearls: A Manual for Valuable Gems
- 3Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- 4How food assistance programs can feed families and nourish their dignity
- 5Instructions to Pick the Ideal SUV Size for Seniors
- Investigating the Financial History of the World: A Succinct Outline
- 6 Hints to Upgrade Your Appeal, In addition to Your Outlook
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- Surveys of Music Collections by Film Stars
- A hunger for new experiences Narratives: Motivating Travel and Experience
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Auschwitz Committee wants German auction of Holocaust items scrapped
- Figure out how to Detect the Best Rooftop Substitution Choices
